UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
UroGen Pharma's ebitda for the twelve months ending Jun 30, 2026 was -$66.30M. For fiscal 2025 it was -$124.56M. The highest annual figure on record is $998.00K in fiscal 2016.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$124.56M | – |
| FY2024 | Dec 31, 2024 | -$96.45M | – |
| FY2023 | Dec 31, 2023 | -$64.73M | – |
| FY2022 | Dec 31, 2022 | -$78.12M | – |
| FY2021 | Dec 31, 2021 | -$91.46M | – |
| FY2020 | Dec 31, 2020 | -$126.32M | – |
| FY2019 | Dec 31, 2019 | -$109.18M | – |
| FY2018 | Dec 31, 2018 | -$76.78M | – |
| FY2017 | Dec 31, 2017 | -$19.75M | -2079.0% |
| FY2016 | Dec 31, 2016 | $998.00K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $211.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.19M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.35M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.59M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.45M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.52M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.92M | – |
| Q4 FY2020 | Dec 31, 2020 | -$27.13M | – |
| Q3 FY2020 | Sep 30, 2020 | -$29.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$38.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$39.74M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.35M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$22.33M | – |
| Q4 FY2018 | Dec 31, 2018 | -$23.82M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.99M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.39M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.44M | – |
See a number that looks wrong?